Study shows that maintenance rituximab is useful for advanced indolent lymphoma

March 11, 2009

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

In a study, sponsored by the National Institutes of Health and conducted by the Eastern Cooperative Oncology Group (ECOG) titled, "Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study," researchers looked at 311 patients with stable or responding disease after CVP therapy. The patients were randomly assigned to observation only or a maintenance rituximab (MR) 375 mg/square meter once per week for 4 weeks every 6 months for 2 years. Results are the first phase III data showing patients with untreated indolent lymphoma can be given (MR) after chemotherapy with minimal toxicity to prevent relapse.

"Low grade lymphoma is very treatable, with patients living many years on the average," says Howard Hochster, M.D. professor of medicine and clinical pharmacology at NYU School of Medicine and director of gastrointestinal oncology and early drug development at the NYU Cancer Institute. "But no one treatment to date has been able to show benefit on long term survival. This reasonably non-toxic antibody can improve disease free survival by several years and possibly effect overall survival. In this group of patients, even 10 years of observation is a little too soon to show survival benefits, but the trend is present."

An improved disease response was seen in 22% of rituximab-treated patients versus just 7% of control subjects. Toxic effects were minimal in both groups. Three year progression-free survival was also higher in the MR group: 68% vs. 33% in controls. In the sub group of 282 patients with follicular lymphoma, the corresponding rates were 64% and 33%. With more than ten years follow-up, the patients receiving MR went nearly 5 years on average before relapse, compared with 1.9 years without .

According to the National Cancer Institute, lymphoma is a disease in which malignant cancer cells form in the lymph system. Indolent lymphoma includes several sub-types of lymphoma that tend to grow and spread slowly, and has few symptoms. It's also called low-grade lymphoma.

The anti-CD20 monoclonal antibody, rituximab was approved for use in follicular lymphoma and indolent lymphoma in 1997 for those no longer responding to chemotherapy. In this setting, the objective response rate was 48% and the agent had rare serious adverse effects, generally limited to infusional toxicity. On the basis of earlier trials, the E1496 study, is the first to test rituximab to maintain response to chemotherapy in indolent lymphoma. Observations from this most recent study add to a substantial body of evidence that the combination of rituximab with chemotherapy is a new standard for patients with indolent lymphoma who require treatment.

The National Cancer Institute funded this multi-center, national trial through ECOG, which began in 1997. Trial centers included the NYU Langone Medical Center in New York City, the Dana Farber Cancer Institute in Boston, Columbia Cancer Agency in Vancouver, the Mayo Clinic in Rochester, Northwestern University in Chicago, Stanford University in Stanford and the University of Maryland in Baltimore.

"This study has led to a new FDA indication for the use of rituximab as maintenance therapy in patients with indolent lymphoma," states Dr. Hochster.

NYU Langone Medical Center / New York University School of Medicine

---

---

	Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler (Author) When neurobiologist Elizabeth M. Adler was diagnosed with non-Hodgkin lymphoma, she learned everything she could about the disease, both to cope with the emotional stress of being diagnosed and to make sure she made the best possible decisions for her treatment. In Living with Lymphoma, she combines her knowledge of lymphoma—both scientific and personal—with the desire to help other patients come to grips with this complex, and often baffling, disease. Adler thoroughly explains the disease, describing the many different kinds of Hodgkin and non-Hodgkin lymphoma, the wide range of symptoms, and the various treatment options available. Convinced that understanding lymphoma's biological basis will help patients make better treatment decisions, Adler explains basic cell biology and how...
	100 Questions & Answers About Lymphoma, Second Edition by Peter Holman (Author) EMPOWER YOURSELF! Written by oncology experts with over 20 years of experience, 100 Questions and Answers About Lymphoma, Second Edition provides authoritative answers to your questions on lymphoma. Featuring the information you need in one concise, easy-to-read volume, 100 Questions and Answers About Lymphoma, Second Edition is an invaluable resource for newly diagnosed patients, survivors, friends or relatives of either. Now, in its Second Edition, this newly updated text features information on the latest, cutting-edge treatments and medication, Hodgkin s and Non-Hodgkin s lymphoma, natural killer cells, T-cell lymphoma, autoimmune diseases, and much more! Comprehensive, insightful, compact, 100 Questions and Answers About Lymphoma, Second Edition is an essential guide for anyone...
	Johns Hopkins Patients' Guide to Lymphoma by Aditya Bardia (Author), Eric Seifter (Author) Johns Hopkins Patients' Guide to Lymphoma is a concise, easy-to-follow how to guide that puts you on the path to wellness by explaining lymphoma treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.
	My Secret Lymphoma by Hanratty, Philip This book is one patient’s sometimes humorous account of living with and being treated for cancer which he likens to having a mistress. Headaches that began in June of 2009 were not diagnosed as Diffuse Large B-Cell Lymphoma until mid December. Given odds of 50/50 by his oncologist he describes the tests, bone marrow biopsies and treatments which included six cycles of R-CHOP, four spinal infusions with other drugs and, while in remission, three 28-day cycles of Revlimid (AKA Lenalidomide). Starting with the R-CHOP treatments he describes the day to day side effects of chemotherapy and his attempts to deal with them. The remainder of the book describes the aftermath of treatment which lasts much longer than one would normally expect.
	Non-Hodgkin Lymphomas by James O. Armitage (Editor), Peter M. Mauch (Editor), Nancy Lee Harris (Editor), Bertrand Coiffier (Editor), Riccardo Dalla-Favera (Editor) Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic. This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders. A companion Website includes the fully searchable text and downloadable...
	Medifocus Guidebook on: Non-Hodgkin's Lymphoma by Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Non-Hodgkin's Lymphoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Hodgkin's Lymphoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Hodgkin's Lymphoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...
	What You Need To Know About: Non- Hodgkin Lymphoma This booklet is about non-Hodgkin lymphoma, a cancer that starts in the immune system. Non-Hodgkin lymphoma is also called NHL. Each year, more than 63,000 Americans learn they have non-Hodgkin lymphoma. This booklet tells about diagnosis, treatment, and supportive care. Learning about the medical care for people with lymphoma can help you take an active part in making choices about your own care.
	Extranodal Lymphomas: Expert Consult - Online and Print, 1e by Judith A. Ferry MD (Author) Extranodal Lymphomas is a practical, easy-to-use guide that helps you accurately diagnose even the most challenging cases. Dr. Judith Ferry and leaders in the field present their expertise to fill the need for a highly-illustrated, authoritative reference that keeps you up to date on histologic, immunophenotypic, genetic, and clinical features, along with risk factors and current nomenclature. This comprehensive resource also features access to the fully searchable text and a downloadable image library online at www.expertconsult.com so you'll have convenient access to everything you need for effective diagnostic decision making.Access the fully searchable text online at www.expertconsult.com, along with a downloadable image bank. See specimens as they appear through the microscope with...
	Skin Lymphoma: The Illustrated Guide by Lorenzo Cerroni (Author), Kevin Gatter (Author), Kerl Helmut (Author) Skin lymphomas are relatively rare and can be easily misdiagnosed as psoriasis or dermatitis. These lymphomas can be fatal. Consequently, those in training in dermatology and pathology need to have a good understanding of the clinical presentations and the pathological correlates of this challenging disease.This updated edition provides:A full-colour illustrated text and atlas that combines pathology with clinical features and treatmentupdated nomenclature according to WHO/EORTC and WHO classificationsImages to expand the diagnostic potentialCases to enhance the scope for teaching and learning
	Understanding Leukemias, Lymphomas and Myelomas by Tariq I. Mughal (Author), Tariq Mughal (Author), John Goldman (Author), John M. Goldman (Author), Sabena T. Mughal (Author), Sabena Mughal (Author) A brand-new edition of the bestselling guide to hematologic malignancies. An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers. Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for...